Sanofi-Lilly Settlement Paves Way For Biosimilar Lantus
This article was originally published in Scrip
Executive Summary
A potential launch of Eli Lilly & Co.'s copycat version of Sanofi's blockbuster Lantus (insulin glargine) in 2016 will put pressure on the entire insulin category, including new drugs like Novo Nordisk AS's Tresiba (insulin degludec) and Sanofi's own follow-on Toujeo.
You may also be interested in...
Mylan Scores IPR Victory, Paving The Way For Follow-On Lantus
US Patent and Trademark Office invalidated two patents covering Sanofi's Lantus vial, clearing the way for Mylan to launch a follow-on product after FDA approval.
Mylan Scores IPR Victory, Paving The Way For Follow-On Lantus
US Patent and Trademark Office invalidated two patents covering Sanofi's Lantus vial, clearing the way for Mylan to launch a follow-on product after FDA approval.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.